CRBU

Caribou Biosciences Inc

0.3802

Nov 12 • 3:59 PM ET -0.0105 (-2.69%)

0.3919

Aftermarket • 7:46 PM ET +0.0117 (3.08%)

Healthcare Biotechnology USA Nano NASD

Peers: ALLO CLLS CRSP FATE AUTL DTIL IPSC NKTX SANA EDIT

| Held by: VTI VXF IWM VTWO IWN IBB SCHA FESM XDNA IWC

Scroll to Statements

Index	RUT
Market Cap	41.08M
Enterprise Value	-27.38M
Income	-102.47M
Sales	9.44M
Book/sh	0.71
Cash/sh	0.88
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	97
IPO	Jul 23, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	4.35
P/B	0.54
P/C	0.43
P/FCF	-
EV/EBITDA	-
EV/Sales	-2.90
Quick Ratio	4.97
Current Ratio	4.97
Debt/Eq	0.34
LT Debt/Eq	0.32
Option/Short	Yes / Yes

EPS (ttm)	-1.03
EPS next Y	-0.94
EPS next Q	-0.10
EPS this Y	47.04%
EPS next Y	-11.88%
EPS next 5Y	-2.05%
EPS past 3/5Y	1.01% -22.62%
Sales past 3/5Y	-6.95% -2.03%
EPS Y/Y TTM	39.34%
Sales Y/Y TTM	1.60%
EPS Q/Q	16.19%
Sales Q/Q	-26.89%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	4.58% 0.63%

Insider Own	9.00%
Insider Trans	0.00%
Inst Own	46.14%
Inst Trans	8.99%
ROA	-64.44%
ROE	-93.80%
ROIC	-100.94%
Gross Margin	73.04%
Oper. Margin	-1140.55%
Profit Margin	-1085.00%
SMA20	-17.41%
SMA50	-55.54%
SMA200	-75.95%
Trades

Shs Outstand	108.04M
Shs Float	98.31M
Short Float	15.15%
Short Ratio	5.51
Short Interest	14.89M
52W High	2.49 -84.73%
52W Low	0.36 4.28%
Volatility	10.38% 9.09%
ATR (14)	0.05
RSI (14)	26.71
Beta	2.49
Rel Volume	0.57
Avg Volume	2.70M
Volume	1,539,735

Perf Week	-7.79%
Perf Month	-17.37%
Perf Quarter	-75.94%
Perf Half Y	-82.23%
Perf YTD	-76.09%
Perf Year	-83.18%
Perf 3Y	-90.12%
Perf 5Y	-98.25%
Perf 10Y	-
Recom	2.20
Target Price	11.75
Prev Close	0.39
Price	0.38
Change %	-2.69%

Consensus

Buy

Avg. Price Target

$11.75

Implied Upside

+2,990.5%

Analysts10incl. previous ratings

Rating Distribution5 Buy · 5 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 08, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral
Oct 07, 2026	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$1	+163.0%
Oct 07, 2026	Downgrade	LLeerink Partners	Outperform → Market Perform	$1	+163.0%
Jun 03, 2024	Downgrade	EEvercore ISI	Outperform → In-line	$13 → $3	+689.1%
Nov 08, 2023	Initiated	CCantor Fitzgerald	Neutral
Oct 31, 2023	Initiated	EEvercore ISI	Outperform	$13	+3,319.3%
Jul 11, 2023	Initiated	TTruist	Buy	$23	+5,949.4%
Feb 18, 2022	Initiated	RRBC Capital Mkts	Outperform	$22	+5,686.4%
Dec 01, 2021	Initiated	OOppenheimer	Outperform	$36	+9,368.7%
Nov 30, 2021	Initiated	HH.C. Wainwright	Buy	$28	+7,264.5%
Nov 15, 2021	Upgrade	CCitigroup	Neutral → Buy	$27	+7,001.5%
Aug 17, 2021	Initiated	SSVB Leerink	Outperform	$32	+8,316.6%
Aug 17, 2021	Initiated	CCitigroup	Neutral	$27	+7,001.5%
Aug 17, 2021	Initiated	BBofA Securities	Buy	$30	+7,790.6%

Nov-05-26 04:05PM	Caribou Biosciences Reports Third Quarter 2026 Financial Results (GlobeNewswire) -7.22% +8.83%
Nov-04-26 09:00AM	Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-08-26 11:23AM	In the hunt for reverse merger targets, Caribou could be prized game (BioPharma Dive) -22.06%
Oct-07-26 11:37AM	Caribou to halt CAR-T work, lay off staff amid challenging funding climate (BioPharma Dive) -45.60%
11:16AM	CAR-T specialist Caribou culls pipeline and seeks exit deal (Pharmaceutical Technology)
06:49AM	Loading…
06:49AM	CRBU Stock Crashes 35% Premarket RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs (Stocktwits)
Oct-06-26 05:17PM	Caribou Biosciences stock plunges 40% on halt of CAR-T programs (Investing.com)
04:05PM	Caribou Biosciences to Evaluate Strategic Alternatives (GlobeNewswire)
Aug-13-26 04:05PM	Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -5.29%
Jul-29-26 09:49AM	BMS and Gilead rule in the CAR-T space. Off-the-shelf developers arent trying to change that. (Pharma Voice)
Jun-29-26 08:00AM	Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (GlobeNewswire) +5.36%
Jun-11-26 08:01AM	Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 (GlobeNewswire) -7.26%
08:00AM	Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting (GlobeNewswire)
May-27-26 04:05PM	Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +6.94%
May-13-26 04:05PM	Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference (GlobeNewswire)
09:30AM	Loading…
May-12-26 09:30AM	Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting (GlobeNewswire)
May-07-26 04:05PM	Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-05-26 04:05PM	Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference (GlobeNewswire)
Mar-31-26 08:00AM	Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy (GlobeNewswire) +10.47%
Mar-05-26 05:15PM	Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.43%
04:05PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-26 08:20AM	EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-02-26 09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-26-26 06:00PM	Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-23-26 08:55PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +6.67% +11.46%
12:06PM	Caribou Biosciences Details Pivotal-Ready Vispa-cel Plan, Flags Need for More Capital at Citi Summit (MarketBeat)
Feb-20-26 12:00PM	Caribou Biosciences (CRBU)'s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street (Insider Monkey)
10:48AM	Genomics Stocks That Deserve a Place in Your Portfolio in 2026 (Zacks)
Feb-12-26 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-10-26 09:40AM	Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:00AM	Loading…
Feb-04-26 08:00AM	Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-13-26 12:00PM	Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why (Zacks)
Dec-01-25 04:05PM	Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 (GlobeNewswire) -8.76%
Nov-12-25 05:30PM	Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -12.17%
04:05PM	Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-25 08:20AM	Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 05:15PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.70%
07:00AM	Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma (GlobeNewswire)
07:00AM	Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies (GlobeNewswire)
06:54AM	Caribou results suggest renewed promise for off-the-shelf cancer cell therapy (BioPharma Dive)
Nov-02-25 04:00PM	Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma (GlobeNewswire)
Aug-25-25 04:05PM	Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference (GlobeNewswire) +6.38%
Aug-12-25 04:05PM	Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.94%
Jul-31-25 07:20AM	Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
May-28-25 04:00PM	Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-25 12:00PM	Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know (Zacks)
May-08-25 05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 04:00PM	Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference (GlobeNewswire) -12.16%
May-01-25 10:01AM	Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know (Zacks) -5.77%
Apr-29-25 10:01AM	Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know (Zacks) +10.44%
Apr-25-25 07:50AM	Caribou cuts pipeline and workforce to focus on lead CAR-T programmes (Pharmaceutical Technology) -11.30%
05:00AM	Caribou, in reversal, scraps autoimmune cell therapy and cuts staff (BioPharma Dive)
Apr-24-25 04:15PM	Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs (GlobeNewswire)
08:10AM	Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
Mar-10-25 05:15PM	Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-18-25 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.19%
05:45AM	Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Feb-07-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-31-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CRBU (PR Newswire) +9.16%
Jan-24-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-17-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-14-25 05:45AM	Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-12-25 07:05PM	Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 (GlobeNewswire)
Jan-07-25 04:00PM	Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.02%
Jan-02-25 08:00AM	Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer (GlobeNewswire) +5.66%
Dec-30-24 03:01PM	Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-16-24 09:55AM	Caribou Biosciences (CRBU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-20-24 04:00PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 06:05PM	Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +7.42%
04:05PM	Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 03:53AM	Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock? (Insider Monkey)
Oct-17-24 03:06PM	STATE STREET CORP's Strategic Acquisition in Caribou Biosciences Inc (GuruFocus.com) -5.83%
Sep-25-24 09:00AM	Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024 (GlobeNewswire)
Sep-03-24 08:00AM	Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML (GlobeNewswire) -8.33%
Aug-26-24 04:00PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:00AM	Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer (GlobeNewswire)
Aug-06-24 06:50PM	Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
10:00AM	Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-09-24 08:00AM	Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board (GlobeNewswire)
Jun-02-24 07:00PM	Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-30-24 04:01PM	Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-24 04:00PM	3 Underappreciated Stocks That Could 10x in 10 Years (InvestorPlace)
May-09-24 05:23AM	Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating (MT Newswires)
May-07-24 10:55PM	CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -6.17%
05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-24-24 10:00AM	Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-15-24 09:00AM	Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
Apr-04-24 04:00PM	Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus (GlobeNewswire)
Mar-14-24 12:00PM	All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy (Zacks)
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey) +11.55%
Mar-12-24 12:37PM	Why Caribou Biosciences Stock Is Crashing Today (Motley Fool) -30.47%
Mar-11-24 04:05PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-24 04:30PM	Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Timothy P	Chief Technology Officer	Feb 25 '26	Sale	1.93	6,228	12,020	73,125	Feb 27 04:01 PM
RUHI AHMAD KHAN	Officer	Feb 24 '26	Proposed Sale	1.96	6,938	13,598		Feb 25 09:42 PM
BARBARA G MCCLUNG	Officer	Feb 24 '26	Proposed Sale	1.96	6,938	13,598		Feb 25 09:41 PM
TIMOTHY KELLY	Officer	Feb 25 '26	Proposed Sale	1.93	6,228	12,051		Feb 25 05:16 PM
Kelly Timothy P	Chief Technology Officer	Feb 24 '26	Sale	1.96	3,147	6,168	79,353	Feb 24 08:54 PM
MCCLUNG BARBARA G	Chief Legal Officer	Feb 24 '26	Sale	1.96	6,938	13,598	481,564	Feb 24 08:54 PM
Khan Ruhi Ahmad	Chief Business Officer	Feb 24 '26	Sale	1.96	6,938	13,598	104,998	Feb 24 08:54 PM
Albertson Tina M.	Chief Medical Officer	Feb 24 '26	Sale	1.96	1,066	2,089	68,523	Feb 24 08:53 PM

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Co-FounderDr. Rachel E. Haurwitz Ph.D.

Chief Financial OfficerMr. Sriram Ryali M.B.A.

J.D.Ms. Barbara G. McClung Esq.

Co-founder & Member of Scientific Advisory BoardDr. Jennifer A. Doudna Ph.D.

Interim Principal Accounting Officer & ControllerMr. Ryan Fischesser

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

CRBU

Caribou Biosciences Inc

Upgrade your Finviz experience

All the Features.
Half the Price.